NextCell Pharma publishes Interim Report 2 2021/2022

April 28, 2022

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period September 1, 2021 – February 28, 2022 The report is available on the company’s website:https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.

Second quarter (2021-12-01 until 2022-02-28)

● Operating income amounted to 1 840 (1 008) TSEK.
● Operating result amounted to -10 212 (-8 149) TSEK.
● Earnings per share* amounted to -0,30 (-0,27) SEK.
● Cash and bank amounted to 118 170 (148 936) TSEK.
● Solidity** amounted to 94,3 (96,8) %.

First half-year (2021-09-01 till 2022-02-28)

● Operating income amounted to 3 187 (2 141) TSEK.
● Operating result amounted to -16 906 (-13 678) TSEK.
● Earnings per share* amounted to -0,22 (-0,51) SEK.
Earnings per share: Profit for the period divided by average number of shares. Average number of shares for the second quarter 2021/2022: 34,379,523 (29,717,519) shares. Average number of shares for the first half year 2021/2022: 34,379,523 (26,540,470) shares. Number of shares in NextCell as of February 28, 2022: 34,379,523 (33,712,857) shares. **Solidity: Own capital's share of the sheet total

‍

Significant events in the second quarter

● NextCell announced in December that it has entered into a cooperation agreement with T.A.D.1, a non-profit association whose purpose is to increase knowledge in society about type 1 diabetes and run projects in support of everyone living with and around T1D. Together we want to spread hope fortype 1 diabetes research and make NextCell's clinical trials visible.
● NextCell announced in January that the company's CEO, Mathias Svahn, had been invited to give a presentation about the company's journey in cell therapy at the Advanced Therapy Week in Miami, USA at the end of January.
● NextCell announced in early February that the company had increased its involvement in FamiCordTx, a joint venture in cell and gene therapy, in a new share issue by approximately 160 kEUR.
● NextCell announced in mid-February that a Pediatric Diabetes Study is underway and that the company is contributing ProTrans and placebo.
● NextCell announced at the end of February that the Canadian probation for ProTrans in COVID-19 will be expanded to a multicenter study
● NextCell announced at the end of October that the clinical trial ProTrans19+SE can begin recruiting patients in the mean dose group. Three patients treated with a low dose of ProTrans have been clinically evaluated and the data have been reviewed by the Safety Committee, which now allows continued medium-dose treatment of ProTrans for severe pneumonia caused by COVID-19.

Significant events after the reporting period

● NextCell announced in early April that the stem cell bank Cellaviva has disclosed stem cells from umbilical cord blood to Rigshospitalet, Denmark's premier hospital. A sibling of the child whose umbilical cord blood was saved in cellovia's biobank, suffers from a serious blood disorderto be treated with stem cells at the Hematology Department at Rigshospitalet.
● NextCell announced in early April that all three children in the age group 12-18 years have been treated with ProTrans. Professor Per-Ola Carlsson and the study team are now moving forward with younger patients, three children in the age group 7-11 years.

This disclosure contains information that NextCell Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 28-04-2022 08:00 CET.

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: 08-735 5595
E-mail: info@nextcellpharma.com

Websites:
www.nextcellpharma.com
www.cellaviva.se
www.cellaviva.dk
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
Instagram: https://www.instagram.com/cellaviva/

About NextCell Pharma AB

NextCell is a phase II cell therapy company with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to take ProTrans to market approval via a Phase III study. ProTrans is in addition to diabetes, used in two clinical trials for Covid-19, in Örebro and Montreal (Canada). The company is in the processes of establishing its own GMP facility for production of ProTrans. The GMP facility is expected to be ready for production of smaller quantities of ProTrans in 2023. NextCell furthermore owns 8,5% in FamicordTX, a CAR-T start-up in oncology and 100 % of Cellaviva, Scandinavia's largest stem cell bank for family saving stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO)

Download attachment Read full press release on Cision (external link)

2024-06-11

The Board of Directors and management sign in addition to subscription commitments

NextCell Pharma AB (publ) ("NextCell" or the "Company") carries out a rights issue of units of up to approximately SEK 40.1 million, which is covered to approximately 100 percent by subscription and guarantee commitments. The company's Board of Directors, management and key employees, who have previously entered into subscription commitments of up to a total of approximately SEK 1.5 million, have now announced that they will register their interest in subscribing for units for a total of approximately SEK 3.3 million, corresponding to 8.2 percent of the rights issue.

Read more Read more

2024-06-10

NextCell publishes supplement to the prospectus regarding the rights issue

THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, CANADA, HONG KONG, BELARUS, RUSSIA OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLISHING OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW. SEE SECTION ”IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE. NextCell Pharma AB (publ) (”NextCell” or the “Company”) has today published a supplement (the “Supplement”) to the EU Growth prospectus, which was approved and registered by the Swedish Financial Supervisory Authority and published on 30 May 2024 (the “Prospectus”). The Supplement has been prepared due to the fact that the Company on 4 June 2024 announced through a press release that the Company had agreed to a so-called top guarantee of a total of approximately SEK 8.0 million in the ongoing rights issue of units in the Company (the “Rights Issue”).

Read more Read more

2024-06-05

Cellaviva becomes an independent company under NextCell Pharma

Cellaviva, the stem cell bank operated by NextCell Pharma AB, has announced its transition to an independent company. This strategic move will enable Cellaviva to further focus on its core mission of providing expectant parents with the opportunity to preserve and store valuable stem cells collected from the placenta and umbilical cord. These cells, which would otherwise be discarded post-birth, offer significant potential for future medical treatments and therapies.

Read more Read more

2024-06-04

NextCell procures top guarantee in ongoing rights issue

THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, CANADA, HONG KONG, BELARUS, RUSSIA OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLISHING OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW. SEE SECTION ”IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE. NextCell Pharma AB (publ) ("NextCell" or the "Company") announces that the Company has agreed to a so-called top guarantee of a total of approximately SEK 8.0 million, corresponding to approximately 20.0 percent of the transaction, from qualified investors in the Company's ongoing rights issue of units of up to approximately SEK 40.1 million before issue costs, in which the subscription period commenced on 31 May 2024 (the "Rights Issue"). With the addition of the top guarantee, the Rights Issue is now covered up to approximately 100 percent by subscription undertakings and guarantee commitments.

Read more Read more

2024-05-31

The subscription period in NextCell’s rights issue commences today

THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, CANADA, HONG KONG, BELARUS, RUSSIA OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLISHING OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW. SEE SECTION ”IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE. Today, 31 May 2024, the subscription period in NextCell Pharma AB (publ)’s (“NextCell” or the “Company”) rights issue of units, which was announced on 24 April 2024 (the “Rights Issue”), commences. The subscription period in the Rights Issue runs until 14 June 2024. Please note, however, that nominees may have a final response date for subscription in the Rights Issue that falls before 14 June 2024.

Read more Read more

2024-05-30

NextCell publishes prospectus in connection with the rights issue of units of approximately SEK 40.1 million

THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, CANADA, HONG KONG, BELARUS, RUSSIA OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLISHING OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW. SEE SECTION ”IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE. NextCell Pharma AB (publ) (”NextCell” or the “Company”) has prepared an EU Growth prospectus (the “Prospectus”) in connection with the Company’s forthcoming issue of units consisting of shares and warrants with preferential rights for existing shareholders (the “Rights Issue”), which was resolved by the Board of Directors on 24 April 2024 and approved by the Extraordinary General Meeting on 27 May 2024.

Read more Read more

2024-05-28

Single treatment with ProTrans demonstrates long-term therapeutic effect over 5 years

NextCell Pharma AB ("NextCell" or the "Company") today announces that patients who were treated with a single dose of ProTrans five years ago in the randomized, placebo-controlled phase II study ProTrans-2 have retained significantly higher endogenous insulin production than patients who received placebo. ProTrans treated patients maintained 57% of their endogenous insulin production compared to 15% in the placebo group. The results are in line with NextCell’s previously reported three year data and demonstrates that ProTrans offers a disease-modifying treatment with long-lasting clinically relevant effect.

Read more Read more

2024-05-27

Bulletin from the Extraordinary General Meeting of NextCell Pharma AB (publ)

At the Extraordinary General Meeting of NextCell Pharma AB (publ) (“NextCell” or the “company”) on 27 May 2024, the following resolutions were made. All resolutions were in accordance with the proposals presented, which are described in detail in the general meeting documents available on the company’s website, www.nextcellpharma.com.

Read more Read more